LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/LRE System and Ortho Consulting Group Partnering
Company News

LRE System and Ortho Consulting Group Partnering

October 21, 2022 2 min read Premium comments

Advertisement

LRE System and Ortho Consulting Group Partnering
Lateral Resurfacing System / Source: LRE System Ltd and Orthoconsulting Group
Secondary#lresystem#orthoconsultinggroup

LRE System Ltd’s restorative elbow joint system is being brought to the global market via a strategic partnership with Ortho Consulting Group (OCG).

The LRE System (lateral resurfacing elbow) is a radiocapitellar resurfacing system. Instead of replacing the elbow joint, the LRE System is designed to “restore the elbow’s normal range of movement.” It can be used as an alternative to total elbow arthroplasty.

For almost 15 years, the lateral resurfacing elbow system has been gathering clinical data in the United Kingdom and Europe. According to the company, the clinical data for the lateral resurfacing elbow system demonstrates that “patients have a significant improvement in elbow function, with lower rates of complications than other surgical treatment options and faster restoration of ability.” Clinical studies on the lateral resurfacing elbow system as surgical treatment for patients with severe degenerative changes were published in the Bone Joint Journal in 2018 and 2019.

OTW spoke with OCG Director Suzanna Everard about the decision to partner with LRE System Ltd. Everard explained to OTW, “As a business consultancy with a dedicated focus within orthopaedics and spine, we are keen to partner with innovative businesses that share our commitment to delivering high-quality patient care. LRE System Ltd has developed a product that provides surgeons with another option to support patients with elbow osteoarthritis who previously had limited treatment choices.”

Everard continued, “The lateral resurfacing elbow system has 15 years of clinical data with patient studies in seven countries, including Italy, Austria, and the Netherlands, providing a good base of understanding for surgeons already using the technology. Utilizing our extensive experience developed over 12 years we look forward to making this treatment available to patients in new markets across Europe and beyond.”

The partnership grants OCG an equity position in LRE System Ltd, an Oxford-based medical technology company. The partnership will allow for the “development and management of a network of distributors in order to engage leading orthopaedic specialists to introduce the LRE System.” Additionally, under the terms of the agreement, OCG will work with LRE System Ltd to “identify and connect with suitable investment partners.”

OTW also asked Everard about the partnership’s goals for the coming year. Everard told OTW, “Having gained the CE mark in 2020, our joint goal is to accelerate product adoption for an elective-surgery option that was subsequently hampered during the pandemic.”

Everard continued, “Our immediate priority is to source investment partners to support commercialization, providing further capital to enhance inventory levels and to explore regulatory pathways in other key markets. OCG has already supported the sourcing, onboarding and contracting of UK extremities distributor Osteotec, and is now exploring further opportunities for the LRE System globally.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy